gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IDXXHealthcareDiagnostics

Idexx Laboratories Inc (IDXX)

$698.55+3.94%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$710.49▼ 1.72% in range
Nov 3, 2025Low $504.70 · High $766.68Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Idexx Laboratories closed at $698.55 on Nov 4, up 3.94%, 8.9% below its 52-week closing high. Volume of 1.4M shares was 2.10× its 20-day average (well above normal).

Split-adjusted performance: +35.5% over one month, +20.6% over six months, -3.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.21B, up 9.9% from a year earlier, with a net margin of 26.1%.

Short interest was 1.9M shares at the Oct 15 settlement (2.5% of float, 3.6 days to cover).

Market cap$55.03B78.8M shares
Revenue · quarter$1.21B+9.9% YoY
Diluted EPS$4.01+17.9% YoY
P/E · TTM46.6×P/S 11.8×
Net margin26.1%Gross 62.9%
Dividend yieldNone
52-week range504.70 – 766.68−8.9% from high
Volume1.4M2.10× 20-day avg
Volatility · 60d48.5%Annualised
Short % of float2.5%3.6 days to cover
Net cash-$651.3MCash $197.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +24.1%1M +35.5%3M +18.4%6M +20.6%YTD +3.3%1Y −3.4%3Y +76.2%5Y +9.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum64
Revenue growth83
Net margin100
Value (low P/E)—
Size100

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short1.9M−0.6% vs prior
Days to cover3.6Settled Oct 15
% of float2.5%
Short vol. 10d58.3%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IDXXIdexx Laboratories$698.55+3.94%+20.6%+9.9%26.1%46.6$55.03B
LNTHLantheus Holdings$101.14+0.34%+17.4%+2.7%19.3%24.0$6.60BCompare
NEOGNeogen$12.46+2.98%+35.7%+6.5%−5.3%—$2.72BCompare
CLDXCelldex Therapeutics$29.93+0.74%−13.0%−97.0%−334104.5%—$2.35BCompare
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72BCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare

News about Idexx Laboratories

All news →
IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings ReactionThe Motley Fool · 2d ago▲ PositiveIdexx Laboratories (IDXX) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research · 2d ago▲ PositiveIdexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research · Oct 26, 2026▲ PositiveHere's How IDEXX Laboratories Is Placed Ahead of Q3 EarningsZacks Investment Research · Oct 23, 2026▲ PositiveWill Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research · Oct 20, 2026▲ Positive

Quick answers

What does Idexx Laboratories do?
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock.
What is IDXX's market cap?
$55.03B, based on the Nov 4 close of $698.55.
What is IDXX's P/E ratio?
46.6× trailing-twelve-month earnings of $1.18B.
Does Idexx Laboratories pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IDXX is sold short?
1.9M shares, 2.5% of float, as of Oct 15, 2026.
What sector is IDXX in?
Healthcare, in the Diagnostics industry.

About Idexx Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

HQ: Westbrook, ME11,000 employeesListed Jun 21, 1991idexx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology